Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Plus Therapeutics Inc's Business Segments
Plus Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Grant
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Grant0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 1 | - |
Revenue by Product & Service Category - FY
- Grant97.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 0 | 97.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Grant0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 1 | - |
Description of Plus Therapeutics Inc
Plus Therapeutics Inc is a pharmaceutical company based in the United States that is focused on developing novel therapies for rare and difficult-to-treat cancers. The company specializes in the discovery and development of targeted, personalized treatments that aim to improve patient outcomes and quality of life.
The company's mission is to develop innovative therapeutic options that address the unmet medical needs of patients with rare and advanced cancers. They are dedicated to translating groundbreaking scientific research into effective clinical solutions that can make a meaningful impact on patients' lives.
One of the key areas of expertise for Plus Therapeutics is nanotechnology-based drug delivery systems. They use proprietary technology platforms to create unique nanoparticles that can be loaded with therapeutic agents, allowing for targeted delivery directly to tumor cells. This approach enhances efficacy while reducing side effects and toxicity compared to traditional chemotherapy methods.
The company's lead product candidate, Rhenium NanoLiposome (RNL™), is an investigational therapy being developed for the treatment of recurrent glioblastoma, a highly aggressive form of brain cancer. RNL™ is designed to deliver a radioactive isotope directly to tumor cells, destroying them while minimizing damage to surrounding healthy tissue.
In addition to RNL™, Plus Therapeutics has a pipeline of other promising candidates in various stages of development. These include DocePLUS, a liposomal formulation of the widely used chemotherapy drug docetaxel, which has the potential to improve treatment outcomes for patients with advanced solid tumors.
Plus Therapeutics also collaborates with leading academic institutions and research organizations to further advance their technology platforms and explore new therapeutic applications. This collaborative approach allows them to tap into a diverse range of scientific expertise and accelerate the development of novel treatments.
Furthermore, the company is committed to conducting rigorous clinical trials to demonstrate the safety and efficacy of their therapies. They work closely with regulatory authorities and seek to obtain regulatory approvals for their products to ensure they can reach patients in need as soon as possible.
Overall, Plus Therapeutics Inc is a forward-thinking pharmaceutical company that is leveraging nanotechnology and personalized medicine to develop innovative therapies for rare and difficult-to-treat cancers. With their dedication to improving patient outcomes and commitment to scientific excellence, they are poised to make a significant impact in the field of oncology.
The company's mission is to develop innovative therapeutic options that address the unmet medical needs of patients with rare and advanced cancers. They are dedicated to translating groundbreaking scientific research into effective clinical solutions that can make a meaningful impact on patients' lives.
One of the key areas of expertise for Plus Therapeutics is nanotechnology-based drug delivery systems. They use proprietary technology platforms to create unique nanoparticles that can be loaded with therapeutic agents, allowing for targeted delivery directly to tumor cells. This approach enhances efficacy while reducing side effects and toxicity compared to traditional chemotherapy methods.
The company's lead product candidate, Rhenium NanoLiposome (RNL™), is an investigational therapy being developed for the treatment of recurrent glioblastoma, a highly aggressive form of brain cancer. RNL™ is designed to deliver a radioactive isotope directly to tumor cells, destroying them while minimizing damage to surrounding healthy tissue.
In addition to RNL™, Plus Therapeutics has a pipeline of other promising candidates in various stages of development. These include DocePLUS, a liposomal formulation of the widely used chemotherapy drug docetaxel, which has the potential to improve treatment outcomes for patients with advanced solid tumors.
Plus Therapeutics also collaborates with leading academic institutions and research organizations to further advance their technology platforms and explore new therapeutic applications. This collaborative approach allows them to tap into a diverse range of scientific expertise and accelerate the development of novel treatments.
Furthermore, the company is committed to conducting rigorous clinical trials to demonstrate the safety and efficacy of their therapies. They work closely with regulatory authorities and seek to obtain regulatory approvals for their products to ensure they can reach patients in need as soon as possible.
Overall, Plus Therapeutics Inc is a forward-thinking pharmaceutical company that is leveraging nanotechnology and personalized medicine to develop innovative therapies for rare and difficult-to-treat cancers. With their dedication to improving patient outcomes and commitment to scientific excellence, they are poised to make a significant impact in the field of oncology.
Plus Therapeutics Inc. is a biopharmaceutical company that specializes in the development of innovative drug therapies, particularly focusing on the treatment of cancers and rare diseases. Below is a detailed description of the segments, products, and services offered by Plus Therapeutics:
Segments
1. Clinical Development Programs:
Plus Therapeutics is engaged in the research and clinical development of novel therapies. The company focuses on advancing its product pipeline through various phases of clinical trials. Clinical development is crucial for validating the efficacy and safety of its drug candidates for regulatory approval and eventual commercialization.
2. Product Pipeline:
Plus Therapeutics has an array of promising drug candidates that are primarily focused on oncology and related fields. The company may have multiple pipelines addressing different types of cancers or therapeutic approaches, allowing for diversification and enhancement of treatment options.
3. Research and Innovation:
The company invests heavily in research and the development of innovative technologies that may enhance therapeutic efficacy and target delivery systems. This segment may focus on novel drug formulations, administration routes, and delivery mechanisms such as targeted therapies.
4. Regulatory Affairs and Compliance:
Navigating the complex regulatory landscape is vital for any biopharmaceutical company. Plus Therapeutics likely has a dedicated segment focused on ensuring compliance with health authorities, preparing for audits, and managing submissions necessary for clinical trial approvals and product marketing authorizations.
5. Partnership and Collaborations:
Plus Therapeutics may engage in strategic partnerships with academic institutions, research organizations, and other biopharmaceutical companies to enable broad-based research initiatives, share technology, and co-develop products that can accelerate time-to-market.
Products
1. Lead Drug Candidates:
- Clofarabine (PNT200): A leading investigational product, Clofarabine is being developed for treating different types of cancers, particularly focusing on pediatric and adult oncology patients. Its mechanism promises impactful outcomes through targeted cellular interactions.
- Radiotherapeutics: Plus Therapeutics is actively involved in developing radiolabeled compounds that aim to selectively target cancer cells while minimizing damage to healthy tissues. These products harness the power of radiation for a precision approach to cancer therapy.
2. Novel Delivery Systems:
The company may be exploring and developing innovative delivery mechanisms such as nanoparticles or liposomal formulations to improve the bioavailability and targeting of its therapeutic agents. These systems aim to enhance patient outcomes by ensuring that higher concentrations of therapeutic agents reach the desired locations with fewer side effects.
3. Combination Therapies:
Plus Therapeutics may be developing combination therapies, integrating its drug candidates with existing treatments to improve efficacy. This approach can potentially enhance patient response rates, reduce treatment resistance, and provide an improved overall therapeutic strategy.
Services
1. Regulatory Support Services:
Plus Therapeutics likely offers expertise in regulatory affairs, helping guide partners and collaborators through the complexities of drug approval processes. This service encompasses regulatory submissions, clinical trial applications, and ongoing communication with health authorities.
2. Clinical Trial Management:
The company possibly offers clinical trial management services, which include protocol development, site selection, patient recruitment, data management, and analysis. This ensures that clinical studies are executed efficiently and according to regulatory standards.
3. Drug Development Consultation:
Plus Therapeutics may provide consultancy services to other biopharmaceutical firms or research organizations on drug development strategies. This includes guidance on the selection of target indications, clinical trial design, and navigating regulatory challenges.
4. Partnership Opportunities:
To foster innovation and accelerate drug development, Plus Therapeutics may offer collaborative opportunities for universities, biotech, and pharmaceutical companies looking to co-develop products or technologies that align with its therapeutic focus.
Conclusion
Plus Therapeutics Inc. is a notable player in the biopharmaceutical industry, focusing on developing novel treatments primarily for cancer and rare diseases. Through its extensive pipeline, robust clinical development programs, innovative delivery systems, and strategic partnerships, the company seeks to transform the therapeutic landscape and improve patient outcomes. With a strong emphasis on research, regulatory compliance, and collaborative efforts, Plus Therapeutics is positioned to make significant contributions to the field of oncology and beyond.
Segments
1. Clinical Development Programs:
Plus Therapeutics is engaged in the research and clinical development of novel therapies. The company focuses on advancing its product pipeline through various phases of clinical trials. Clinical development is crucial for validating the efficacy and safety of its drug candidates for regulatory approval and eventual commercialization.
2. Product Pipeline:
Plus Therapeutics has an array of promising drug candidates that are primarily focused on oncology and related fields. The company may have multiple pipelines addressing different types of cancers or therapeutic approaches, allowing for diversification and enhancement of treatment options.
3. Research and Innovation:
The company invests heavily in research and the development of innovative technologies that may enhance therapeutic efficacy and target delivery systems. This segment may focus on novel drug formulations, administration routes, and delivery mechanisms such as targeted therapies.
4. Regulatory Affairs and Compliance:
Navigating the complex regulatory landscape is vital for any biopharmaceutical company. Plus Therapeutics likely has a dedicated segment focused on ensuring compliance with health authorities, preparing for audits, and managing submissions necessary for clinical trial approvals and product marketing authorizations.
5. Partnership and Collaborations:
Plus Therapeutics may engage in strategic partnerships with academic institutions, research organizations, and other biopharmaceutical companies to enable broad-based research initiatives, share technology, and co-develop products that can accelerate time-to-market.
Products
1. Lead Drug Candidates:
- Clofarabine (PNT200): A leading investigational product, Clofarabine is being developed for treating different types of cancers, particularly focusing on pediatric and adult oncology patients. Its mechanism promises impactful outcomes through targeted cellular interactions.
- Radiotherapeutics: Plus Therapeutics is actively involved in developing radiolabeled compounds that aim to selectively target cancer cells while minimizing damage to healthy tissues. These products harness the power of radiation for a precision approach to cancer therapy.
2. Novel Delivery Systems:
The company may be exploring and developing innovative delivery mechanisms such as nanoparticles or liposomal formulations to improve the bioavailability and targeting of its therapeutic agents. These systems aim to enhance patient outcomes by ensuring that higher concentrations of therapeutic agents reach the desired locations with fewer side effects.
3. Combination Therapies:
Plus Therapeutics may be developing combination therapies, integrating its drug candidates with existing treatments to improve efficacy. This approach can potentially enhance patient response rates, reduce treatment resistance, and provide an improved overall therapeutic strategy.
Services
1. Regulatory Support Services:
Plus Therapeutics likely offers expertise in regulatory affairs, helping guide partners and collaborators through the complexities of drug approval processes. This service encompasses regulatory submissions, clinical trial applications, and ongoing communication with health authorities.
2. Clinical Trial Management:
The company possibly offers clinical trial management services, which include protocol development, site selection, patient recruitment, data management, and analysis. This ensures that clinical studies are executed efficiently and according to regulatory standards.
3. Drug Development Consultation:
Plus Therapeutics may provide consultancy services to other biopharmaceutical firms or research organizations on drug development strategies. This includes guidance on the selection of target indications, clinical trial design, and navigating regulatory challenges.
4. Partnership Opportunities:
To foster innovation and accelerate drug development, Plus Therapeutics may offer collaborative opportunities for universities, biotech, and pharmaceutical companies looking to co-develop products or technologies that align with its therapeutic focus.
Conclusion
Plus Therapeutics Inc. is a notable player in the biopharmaceutical industry, focusing on developing novel treatments primarily for cancer and rare diseases. Through its extensive pipeline, robust clinical development programs, innovative delivery systems, and strategic partnerships, the company seeks to transform the therapeutic landscape and improve patient outcomes. With a strong emphasis on research, regulatory compliance, and collaborative efforts, Plus Therapeutics is positioned to make significant contributions to the field of oncology and beyond.